title: Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration.
authors.affiliation: Pfizer, Collegeville, Pennsylvania, USA.
authors.forename: Lisa
authors.initials: L
authors.lastname: Marshall
authors.affiliation: Pfizer, Andover, Massachusetts, USA.
authors.forename: Timothy
authors.initials: T
authors.lastname: Hickling
authors.affiliation: Pfizer UK, Surrey, UK.
authors.forename: David
authors.initials: D
authors.lastname: Bill
authors.affiliation: Pfizer, Collegeville, Pennsylvania, USA.
authors.forename: Ehab
authors.initials: E
authors.lastname: Mahgoub
mesh_terms: D018501:Antirheumatic Agents; D001172:Arthritis, Rheumatoid; D059451:Biosimilar Pharmaceuticals; D000068800:Etanercept; D018124:Receptors, Tumor Necrosis Factor
chemical_list: D018501:Antirheumatic Agents; D059451:Biosimilar Pharmaceuticals; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept
keywords: Anti-TNF; DMARDs (biologic); Rheumatoid Arthritis